Maryland Peptide Research Regulatory Overview
Federal and state regulatory context for research-grade peptide compounds in Maryland. Informational summary for scientific researchers and research institutions.
Disclaimer: This page provides general regulatory context for informational purposes only and does not constitute legal advice. Researchers should consult applicable federal and state regulations and qualified legal counsel before making any decisions based on this content.
Federal Regulatory Context
Given that NIH and FDA are headquartered in Maryland, federal research chemical regulations are particularly directly relevant to Maryland researchers. Research-grade peptide compounds available from research chemical suppliers are not currently scheduled under the federal CSA and are available for in vitro laboratory research without DEA controlled substance registration requirements. NIH-funded researchers in Maryland are additionally subject to NIH grant terms that require responsible research conduct and compliance with applicable federal regulations.
Maryland State Context
The Maryland Controlled Dangerous Substances Act tracks federal CSA scheduling and does not currently impose scheduling restrictions on unscheduled research-grade peptide compounds. Maryland does not maintain a state analog act applicable to standard research peptide compound classes. Researchers at Maryland institutions, including those on the NIH campus in Bethesda, should consult institutional compliance offices for guidance on research chemical procurement requirements applicable to their specific institutional context.
Research Overview
Maryland occupies a unique position in the US biomedical research landscape as the home of the National Institutes of Health (NIH) in Bethesda, Johns Hopkins University School of Medicine, the University of Maryland School of Medicine, the FDA headquarters in Silver Spring, and the National Cancer Institute. This concentration of federal research infrastructure and major academic medical centers makes Maryland one of the most research-intensive states in the nation. The Maryland Controlled Dangerous Substances Act (Maryland Code, Criminal Law Article, Section 5-101 et seq.) establishes state scheduling that tracks federal CSA scheduling and does not currently include unscheduled research-grade peptide compounds such as BPC-157, TB-500, GHK-Cu, NAD+, and Epithalon. Maryland research institutions should operate within appropriate institutional compliance frameworks.
- •Johns Hopkins University School of Medicine
- •National Institutes of Health
- •University of Maryland School of Medicine
Commonly Researched Compounds
Research-grade compounds commonly procured by institutions in Maryland for in vitro and preclinical research programs.
Frequently Asked Questions
Legal Disclaimer
The information on this page is provided for general informational and educational purposes only. It does not constitute legal advice and should not be relied upon as such. Laws and regulations governing research chemicals, peptides, and related compounds vary by jurisdiction and are subject to change. Researchers and organizations should consult a qualified legal professional familiar with federal and state law applicable to their specific situation before making any decisions based on this content. Spartan Peptides does not provide legal counsel and makes no representations regarding the legal status of any compound in any specific jurisdiction.
Explore All Research-Grade Compounds
Browse the full Spartan Peptides research compound catalog. All compounds are research-grade, supplied as lyophilized powder with certificate of analysis, for in vitro laboratory research use only.